57999-49-2

Usage

Uses

Used in Pharmaceutical Industry:
2-(3-Bromophenoxy)tetrahydro-2H-pyran is used as an antihistamine for treating allergic symptoms, such as itching, hives, and runny nose, by blocking the action of histamine. It is also used as a mild sedative to provide relief from sleep disturbances caused by allergies or the common cold.
Used in Over-the-Counter Medications:
2-(3-Bromophenoxy)tetrahydro-2H-pyran is used as an active ingredient in various over-the-counter medications, such as cold and allergy remedies, due to its effectiveness in relieving symptoms and its generally well-tolerated nature. It is often combined with other ingredients, such as decongestants or pain relievers, to provide comprehensive relief for cold and allergy sufferers.
Used in Allergy Management:
2-(3-Bromophenoxy)tetrahydro-2H-pyran is used as a component in allergy management strategies, helping individuals with seasonal allergies or other types of hypersensitivity reactions to better cope with their symptoms. By reducing the histamine-induced inflammation and other allergic responses, it contributes to improved quality of life for those affected by allergies.
Used in Research and Development:
2-(3-Bromophenoxy)tetrahydro-2H-pyran is utilized in research and development for the study of histamine's role in allergic reactions and the development of new antihistamine medications. Its properties and effects on histamine pathways provide valuable insights for scientists working in the field of allergy and immunology.

InChI:InChI=1/C11H13BrO2/c12-9-4-3-5-10(8-9)14-11-6-1-2-7-13-11/h3-5,8,11H,1-2,6-7H2

Upstream product

• 110-87-2 3,4-dihydro-2H-pyran 
• 591-20-8 3-Bromophenol 

Downstream Products

• 117821-99-5 4-m-hydroxyphenyl-1-methyl-4-propionyloxypiperidine 
• 80165-54-4 Dimethyl-{8-[3-(tetrahydro-pyran-2-yloxy)-phenyl]-1,4-dioxa-spiro[4.5]dec-8-yl}-amine 
• 83647-26-1 1-[4-(2-Dimethylamino-ethoxy)-phenyl]-2-phenyl-1-[3-(tetrahydro-pyran-2-yloxy)-phenyl]-butan-1-ol 
• 88642-64-2 Butyl-methyl-{8-[3-(tetrahydro-pyran-2-yloxy)-phenyl]-1,4-dioxa-spiro[4.5]dec-8-yl}-amine 
• 875273-45-3 1-benzyl-3-[3-(tetrahydropyran-2-yloxy)-phenyl]-piperidin-3-ol 
• 1207067-33-1 C₂₃H₂₂FNO₄ 
• 142402-62-8 (3-((tetrahydro-2H-pyran-2-yl)oxy)phenyl)magnesium bromide 

Relevant academic research and scientific papers

Synthesis and evaluation of (E)-2-(5-phenylpent-2-en-4-ynamido)cyclohex-1-ene-1-carboxylate derivatives as HCA2 receptor agonists

Novel series of compounds consisting of 2-amidocyclohex-1-ene carboxylate and phenyl parts which are connected by enyne (compounds 2a–f), but-1-yne (compounds 4a–j), and phenylethylene (compounds 5a–f) linkers as HCA2 full agonists were designed and their

1-Benzyl-4-phenyl-1H-1,2,3-triazoles improve the transcriptional functions of estrogen-related receptor γ and promote the browning of white adipose

The estrogen-related receptor γ (ERRγ) is a potential molecular target for the development of small molecules to stimulate the adipose browning process, which may represent a novel attractive strategy to treat obesity related disorders. The receptor possesses a very small ligand binding cavity and therefore identification of small molecule ERRγ modulators is a considerable challenge. We have successfully designed and synthesized a series of 1-benzyl-4-phenyl-1H-1,2,3-triazoles and demonstrated that they improve the transcriptional functions of ERRγ, potently elevating both the mRNA levels and the protein levels of ERRγ downstream targets. One of the most promising compounds, 4-(1-(4-iso-propylbenzyl)-1H-1,2,3-triazol-4-yl)benzene-1,2-diol (2e) was further shown to directly bind with the ERRγ ligand binding domain (ERRγ-LBD) in an isothermal calorimetric (ITC) assay and to thermally stabilize ERRγ-LBD protein by increasing its melting temperature (Tm) as demonstrated by circular dichroism (CD) spectroscopy. Furthermore, 2e potently stimulates the adipocyte browning process and induces mitochondrial biogenesis both in vitro and in vivo, suggesting the considerable therapeutic potential of this compound for the treatment of obesity and related disorders.

Tetrahydropyranylation of alcohols in the presence of a slightly basic, heterogeneous titanium catalyst

4 ? molecular sieve modified with titanium (IV) is an efficient heterogeneous catalyst for the tetrahydropyranylation of alcohols under mild, slightly basic reaction conditions. The catalyst can be reused with good yield after a simple treatment with dichloromethane.

Traceless solid-phase synthesis of trifluoromethylarenes

Save the best for last: In the first method for the trifluoromethylation of immobilized arenes, the aryl halides are attached through a dithioester linkage to the Merrifield resin and then functionalized by means of numerous reactions including transition

Synthesis and characterization of achiral bent-core liquid crystalline molecules containing salicylaldimine-based with a wide temperature range of SmCP phase

The design and synthesis of a series bent-core materials base on a 3,4'-biphenyldiol central core containing salicylaldimine-based and two terminal tetradecyloxy tails are reported. In addition, the effects of lateral substituents (R = F and Cl) at the biphenyl core into 3'-position are examined. These substituents have a strong influence in reducing the clearing temperatures and increasing temperature range of SmCP phase. Upon cooling process the isotropic liquid, compound SB-Cl exhibits the lowest clearing transition temperature of 180 oC and the widest SmCP phase range of 129 °C. The mesophase behaviour were investigated by polarizing optical microscopy (POM), differential scanning calorimetry (DSC), X-ray diffraction (XRD), and electro-optical (EO) measurements in the mesophase temperature range.

Hydroxy derivatives of tamoxifen

In the exploration of the structural features that affect the RBA (binding affinity for the estrogen receptor of rat uterus relative to that of estradiol) in the tamoxifen [trans-(Z)-1-[4-(dimethylamino)ethoxy]-1,2-diphenyl-1-butene] series, several derivatives variously substituted in the 1-phenyl group have been synthesized. In the tamoxifen series, the descriptors E and Z, which define the configuration of the geometrical isomers and depend on the location and nature of substituents in the aromatic moieties and the ethyl group, may vary, although the relative configuration (cis or trans) does not. In order to avoid confusion the terms cis and trans will be used in this paper to refer to the relative positions of the 4-[2-(dimethylamino)ethoxy]phenyl and ethyl (or hydroxyethyl, hydroxypropyl, or bromo) substituents attached to the ethene moiety]. The final stage of each synthesis involved acid-catalyzed dehydration of a tertiary alcohol, and, in contrast to the known 3- and 4-hydroxy derivatives which were obtained as near-equimolar cis,trans mixtures, only the trans forms of the 2-hydroxy, 2-methyl, 2,4-dihydroxy, and 4-hydroxy-2-methyl derivatives were obtained. Also, in contrast to the trans forms of the 3- and 4-hydroxy derivatives, which are readily equilibrated to cis,trans mixtures, the trans 2-hydroxy derivative could not be isomerized. Tamoxifen and 2-methyltamoxifen had similar RBA's (~1% of that of E2), but that of 2-hydroxytamoxifen was much lower (0.1%). Introduction of a second hydroxyl group (2,4-dihydroxy derivative) enhanced the RBA, and for the 4-hydroxy-2-methyl derivative, the RBA and growth inhibitory activity against the MCF-7 mammary tumor cell line in vitro were high and comparable to those of 4-hydroxytamoxifen, a metabolite of the parent drug. Tamoxifen derivatives hydroxylated at positions 3 or 4 of the 1-butene moiety and the 5-hydroxy-1-pentene analogue were also synthesized, but they had very low RBA values.

3-Keto-19-nor-Δ4,9-steroids

Novel 3-keto-19-nor-Δ4,9-steroids of the formula STR1